Literature DB >> 19155521

Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.

Alfonso J García-Piñeres1, Allan Hildesheim, Lori Dodd, Troy J Kemp, Jun Yang, Brandie Fullmer, Clayton Harro, Douglas R Lowy, Richard A Lempicki, Ligia A Pinto.   

Abstract

Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155521      PMCID: PMC2701477          DOI: 10.4049/jimmunol.182.3.1706

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Authors:  T G Evans; W Bonnez; R C Rose; S Koenig; L Demeter; J A Suzich; D O'Brien; M Campbell; W I White; J Balsley; R C Reichman
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

3.  Down-regulation of macrophage CD9 expression by interferon-gamma.

Authors:  Xue-Qing Wang; Glenn F Evans; M Leticia Alfaro; Steven H Zuckerman
Journal:  Biochem Biophys Res Commun       Date:  2002-01-25       Impact factor: 3.575

4.  Dipeptidyl peptidase IV (DP IV/CD26) mRNA expression in PWM-stimulated T-cells is suppressed by specific DP IV inhibition, an effect mediated by TGF-beta(1).

Authors:  M Arndt; U Lendeckel; A Spiess; J Faust; K Neubert; D Reinhold; S Ansorge
Journal:  Biochem Biophys Res Commun       Date:  2000-08-02       Impact factor: 3.575

5.  Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro.

Authors:  M P Rudolf; S C Fausch; D M Da Silva; W M Kast
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

6.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

7.  Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

Authors:  Ligia A Pinto; Jessica Edwards; Philip E Castle; Clayton D Harro; Douglas R Lowy; John T Schiller; Dora Wallace; William Kopp; Joseph W Adelsberger; Michael W Baseler; Jay A Berzofsky; Allan Hildesheim
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

8.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  The block in immunoglobulin class switch recombination caused by activation-induced cytidine deaminase deficiency occurs prior to the generation of DNA double strand breaks in switch mu region.

Authors:  Nadia Catalan; Françoise Selz; Kohsuke Imai; Patrick Revy; Alain Fischer; Anne Durandy
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

10.  Protective immunity against Helicobacter is characterized by a unique transcriptional signature.

Authors:  Anne Mueller; Jani O'Rourke; Pauline Chu; Charles C Kim; Philip Sutton; Adrian Lee; Stanley Falkow
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

View more
  11 in total

1.  Type I interferon related genes are common genes on the early stage after vaccination by meta-analysis of microarray data.

Authors:  Junnan Zhang; Jie Shao; Xing Wu; Qunying Mao; Yiping Wang; Fan Gao; Wei Kong; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles.

Authors:  Fatma M Shebl; Ligia A Pinto; Alfonso García-Piñeres; Richard Lempicki; Marcus Williams; Clayton Harro; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

Review 3.  Systems vaccinology: learning to compute the behavior of vaccine induced immunity.

Authors:  Helder I Nakaya; Shuzhao Li; Bali Pulendran
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011-10-19

Review 4.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

Review 5.  Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.

Authors:  Megan M O'Meara; Mary L Disis
Journal:  OMICS       Date:  2011-07-06

6.  Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women.

Authors:  Morgan A Marks; Patti E Gravitt; Robert D Burk; Yevgeniy Studentsov; Homayoon Farzadegan; Sabra L Klein
Journal:  Clin Vaccine Immunol       Date:  2010-02-03

7.  Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model.

Authors:  Daniel W Sepkovic; Johann Stein; Antoine D Carlisle; H Barbara Ksieski; Karen Auborn; H Leon Bradlow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

8.  Anopheles gambiae antiviral immune response to systemic O'nyong-nyong infection.

Authors:  Joanna Waldock; Kenneth E Olson; George K Christophides
Journal:  PLoS Negl Trop Dis       Date:  2012-03-13

Review 9.  New developments and concepts related to biomarker application to vaccines.

Authors:  S Sohail Ahmed; Steve Black; Jeffrey Ulmer
Journal:  Microb Biotechnol       Date:  2011-09-06       Impact factor: 5.813

10.  Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches.

Authors:  Jie Shao; Junnan Zhang; Xing Wu; Qunying Mao; Pan Chen; Fengcai Zhu; Miao Xu; Wei Kong; Zhenglun Liang; Junzhi Wang
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.